Respiratory syncytial virus vaccines for otitis media (Q34133038)

31 July 2017

1 reference

title

Respiratory syncytial virus vaccines for otitis media (English)

1 reference

31 July 2017

1

Anderson LJ

1 reference

31 July 2017

language of work or name

English

0 references

publication date

1 December 2000

1 reference

31 July 2017

1 reference

31 July 2017

volume

19 Suppl 1

1 reference

31 July 2017

page(s)

S59-65

1 reference

Respiratory-syncytial-virus infections, reinfections and immunity. A prospective, longitudinal study in young children

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Immunity to and frequency of reinfection with respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial viral infection in children with compromised immune function

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial viral infection in infants with congenital heart disease

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Association between respiratory syncytial virus outbreaks and lower respiratory tract deaths of infants and young children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial virus that lacks open reading frame 2 of the M2 gene (M2-2) has altered growth characteristics and is attenuated in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Immune and histopathological responses in animals vaccinated with recombinant vaccinia viruses that express individual genes of human respiratory syncytial virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

CD8+ T cells control Th2-driven pathology during pulmonary respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Atypical pulmonary eosinophilia is mediated by a specific amino acid sequence of the attachment (G) protein of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

A Longitudinal Study of Respiratory Viruses and Bacteria in the Etiology of Acute Otitis Media with Effusion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Prevalence of Various Respiratory Viruses in the Middle Ear during Acute Otitis Media

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Detection of rhinovirus, respiratory syncytial virus, and coronavirus infections in acute otitis media by reverse transcriptase polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Identification of respiratory virus antigens in middle ear fluids of children with acute otitis media

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Incidence of Adenovirus and Respiratory Syncytial Virus in Chronic Otitis Media with Effusion Using the Polymerase Chain Reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Polymerase chain reaction-based detection of rhinovirus, respiratory syncytial virus, and coronavirus in otitis media with effusion

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial virus-enriched globulin for the prevention of acute otitis media in high risk children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Immunological properties of plaque purified strains of live attenuated respiratory syncytial virus (RSV) for human vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Immunogenicity and pathogenicity of a triple temperature-sensitive modified respiratory syncytial virus in adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

The two amino acid substitutions in the L protein of cpts530/1009, a live-attenuated respiratory syncytial virus candidate vaccine, are independent temperature-sensitive and attenuation mutations

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

A single nucleotide substitution in the transcription start signal of the M2 gene of respiratory syncytial virus vaccine candidate cpts248/404 is the major determinant of the temperature-sensitive and attenuation phenotypes

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Priming with live respiratory syncytial virus (RSV) prevents the enhanced pulmonary inflammatory response seen after RSV challenge in BALB/c mice immunized with formalin-inactivated RSV.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Protection of cotton rats against human respiratory syncytial virus by vaccination with a novel chimeric FG glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Protective efficacy against respiratory syncytial virus following murine neonatal immunization with BBG2Na vaccine: influence of adjuvants and maternal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

The immunostimulating complex (ISCOM) is an efficient mucosal delivery system for respiratory syncytial virus (RSV) envelope antigens inducing high local and systemic antibody responses

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Formulation of the purified fusion protein of respiratory syncytial virus with the saponin QS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Adjuvants influence the quantitative and qualitative immune response in BALB/c mice immunized with respiratory syncytial virus FG subunit vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Humoral, mucosal, and cellular immune response to topical immunization with a subunit respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Protection against respiratory syncytial virus infection by DNA immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Immunogenicity of recombinant adenovirus-respiratory syncytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs and a chimpanzee

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

Middle ear disease and the practice of pediatrics. Burden during the first five years of life

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2800%2900280-2

7 January 2021

10.1016/S0264-410X(00)00280-2

Identifiers

DOI

1 reference

31 July 2017

1 reference